Immunologic phenotype of patients with long-COVID syndrome of 1-year duration

BackgroundThe pathophysiology of long-COVID remains unknown, and information is particularly limited for symptoms of very long duration. We aimed to assess the serological, T-cell immune responses and ANA titers of patients with long-COVID-19 syndrome of 1-year duration. MethodsProspective, longitud...

Descripción completa

Detalles Bibliográficos
Autores: Garcia-Abellan, J, Fernandez, M, Padilla, S, Garcia, JA, Agullo, V, Lozano, V, Ena, N, Garcia-Sanchez, L, Gutierrez, F, Masia, M
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:España
Institución:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Repositorio:r-FISABIO. Repositorio Institucional de Producción Científica
OAI Identifier:oai:fisabio.fundanetsuite.com:p13930
Acceso en línea:https://fisabio.portalinvestigacion.com/publicaciones/13930
Access Level:acceso abierto
Palabra clave:COVID-19
long COVID
post-COVID-19 syndrome
antibody response
antinuclear antibodies (ANA)
one year
T-cell immune response
cellular immune response
humoral immune response
id ES_eaca97b7924f49ec0cfed4eb4dda82ca
oai_identifier_str oai:fisabio.fundanetsuite.com:p13930
network_acronym_str ES
network_name_str España
repository_id_str
spelling Immunologic phenotype of patients with long-COVID syndrome of 1-year durationGarcia-Abellan, JFernandez, MPadilla, SGarcia, JAAgullo, VLozano, VEna, NGarcia-Sanchez, LGutierrez, FMasia, MCOVID-19long COVIDpost-COVID-19 syndromeantibody responseantinuclear antibodies (ANA)one yearT-cell immune responsecellular immune responsehumoral immune responseBackgroundThe pathophysiology of long-COVID remains unknown, and information is particularly limited for symptoms of very long duration. We aimed to assess the serological, T-cell immune responses and ANA titers of patients with long-COVID-19 syndrome of 1-year duration. MethodsProspective, longitudinal study of hospitalized COVID-19 patients followed-up for 12 months. Sequential blood samples and COVID-19 symptom questionnaires (CSQ) were obtained, and humoral and cellular immune responses, antinuclear antibodies (ANA) and inflammation biomarkers were analyzed. ResultsOf 154 patients discharged from hospital, 72 non-vaccinated with available CSQ in all visits were included. Of them, 14 (19.4%) reported persistent symptoms both at 6-months and 12-months, mainly asthenia (15.3%), myalgia (13.9%), and difficulty concentrating/memory loss (13.9%). Symptomatic patients were more frequently women, smokers, showed higher WHO severity score, and a trend to higher ICU admission. In the adjusted analysis, long-COVID syndrome was associated with lower frequency of detectable neutralizing antibodies (adjusted hazard ratio [aHR] 0.98; 95% confidence interval [CI], 0.97-0.99) and lower SARS-CoV-2-S1/S2 titers (aHR [95%CI] 0.14 [0.03-0.65]). T-cell immune response measured with a SARS-CoV-2-interferon-gamma release assay was not different between groups. There was a higher frequency of positive ANA titers (>= 160) in symptomatic patients (57.1% vs 29.3%, p=0.04), that was attenuated after adjustment aHR [95% CI] 3.37 [0.84-13.57], p=0.087. Levels of C-reactive protein and D-dimer were higher during follow-up in symptomatic patients, but with no differences at 12 months. ConclusionPatients with 1-year duration long-COVID-19 syndrome exhibit a distinct immunologic phenotype that includes a poorer SARS-CoV-2 antibody response, low-degree chronic inflammation that tends to mitigate, and autoimmunity.FRONTIERS MEDIA SA2022info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://fisabio.portalinvestigacion.com/publicaciones/13930Frontiers in ImmunologyISSN: 16643224reponame:r-FISABIO. Repositorio Institucional de Producción Científicainstname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)Inglésinfo:eu-repo/semantics/openAccessoai:fisabio.fundanetsuite.com:p139302026-06-11T12:45:17Z
dc.title.none.fl_str_mv Immunologic phenotype of patients with long-COVID syndrome of 1-year duration
title Immunologic phenotype of patients with long-COVID syndrome of 1-year duration
spellingShingle Immunologic phenotype of patients with long-COVID syndrome of 1-year duration
Garcia-Abellan, J
COVID-19
long COVID
post-COVID-19 syndrome
antibody response
antinuclear antibodies (ANA)
one year
T-cell immune response
cellular immune response
humoral immune response
title_short Immunologic phenotype of patients with long-COVID syndrome of 1-year duration
title_full Immunologic phenotype of patients with long-COVID syndrome of 1-year duration
title_fullStr Immunologic phenotype of patients with long-COVID syndrome of 1-year duration
title_full_unstemmed Immunologic phenotype of patients with long-COVID syndrome of 1-year duration
title_sort Immunologic phenotype of patients with long-COVID syndrome of 1-year duration
dc.creator.none.fl_str_mv Garcia-Abellan, J
Fernandez, M
Padilla, S
Garcia, JA
Agullo, V
Lozano, V
Ena, N
Garcia-Sanchez, L
Gutierrez, F
Masia, M
author Garcia-Abellan, J
author_facet Garcia-Abellan, J
Fernandez, M
Padilla, S
Garcia, JA
Agullo, V
Lozano, V
Ena, N
Garcia-Sanchez, L
Gutierrez, F
Masia, M
author_role author
author2 Fernandez, M
Padilla, S
Garcia, JA
Agullo, V
Lozano, V
Ena, N
Garcia-Sanchez, L
Gutierrez, F
Masia, M
author2_role author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv COVID-19
long COVID
post-COVID-19 syndrome
antibody response
antinuclear antibodies (ANA)
one year
T-cell immune response
cellular immune response
humoral immune response
topic COVID-19
long COVID
post-COVID-19 syndrome
antibody response
antinuclear antibodies (ANA)
one year
T-cell immune response
cellular immune response
humoral immune response
description BackgroundThe pathophysiology of long-COVID remains unknown, and information is particularly limited for symptoms of very long duration. We aimed to assess the serological, T-cell immune responses and ANA titers of patients with long-COVID-19 syndrome of 1-year duration. MethodsProspective, longitudinal study of hospitalized COVID-19 patients followed-up for 12 months. Sequential blood samples and COVID-19 symptom questionnaires (CSQ) were obtained, and humoral and cellular immune responses, antinuclear antibodies (ANA) and inflammation biomarkers were analyzed. ResultsOf 154 patients discharged from hospital, 72 non-vaccinated with available CSQ in all visits were included. Of them, 14 (19.4%) reported persistent symptoms both at 6-months and 12-months, mainly asthenia (15.3%), myalgia (13.9%), and difficulty concentrating/memory loss (13.9%). Symptomatic patients were more frequently women, smokers, showed higher WHO severity score, and a trend to higher ICU admission. In the adjusted analysis, long-COVID syndrome was associated with lower frequency of detectable neutralizing antibodies (adjusted hazard ratio [aHR] 0.98; 95% confidence interval [CI], 0.97-0.99) and lower SARS-CoV-2-S1/S2 titers (aHR [95%CI] 0.14 [0.03-0.65]). T-cell immune response measured with a SARS-CoV-2-interferon-gamma release assay was not different between groups. There was a higher frequency of positive ANA titers (>= 160) in symptomatic patients (57.1% vs 29.3%, p=0.04), that was attenuated after adjustment aHR [95% CI] 3.37 [0.84-13.57], p=0.087. Levels of C-reactive protein and D-dimer were higher during follow-up in symptomatic patients, but with no differences at 12 months. ConclusionPatients with 1-year duration long-COVID-19 syndrome exhibit a distinct immunologic phenotype that includes a poorer SARS-CoV-2 antibody response, low-degree chronic inflammation that tends to mitigate, and autoimmunity.
publishDate 2022
dc.date.none.fl_str_mv 2022
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://fisabio.portalinvestigacion.com/publicaciones/13930
url https://fisabio.portalinvestigacion.com/publicaciones/13930
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv FRONTIERS MEDIA SA
publisher.none.fl_str_mv FRONTIERS MEDIA SA
dc.source.none.fl_str_mv Frontiers in Immunology
ISSN: 16643224
reponame:r-FISABIO. Repositorio Institucional de Producción Científica
instname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
instname_str Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
reponame_str r-FISABIO. Repositorio Institucional de Producción Científica
collection r-FISABIO. Repositorio Institucional de Producción Científica
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869423170391375872
score 15.812455

Similares en LA Referencia